These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 33656015)

  • 1. Lasmiditan for acute treatment of migraine.
    Parikh S
    Drugs Today (Barc); 2021 Feb; 57(2):89-100. PubMed ID: 33656015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lasmiditan mechanism of action - review of a selective 5-HT
    Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
    J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The selective 5-HT
    Vila-Pueyo M; Page K; Murdock PR; Loraine HJ; Woodrooffe AJ; Johnson KW; Goadsby PJ; Holland PR
    Br J Pharmacol; 2022 Feb; 179(3):358-370. PubMed ID: 34600443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted 5-HT
    Vila-Pueyo M
    Neurotherapeutics; 2018 Apr; 15(2):291-303. PubMed ID: 29488143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system.
    Labastida-Ramírez A; Rubio-Beltrán E; Haanes KA; Chan KY; Garrelds IM; Johnson KW; Danser AHJ; Villalón CM; MaassenVanDenBrink A
    Pain; 2020 May; 161(5):1092-1099. PubMed ID: 31977930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine.
    Raffaelli B; Israel H; Neeb L; Reuter U
    Expert Opin Pharmacother; 2017 Sep; 18(13):1409-1415. PubMed ID: 28749698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lasmiditan for the acute treatment of migraine.
    DeJulio PA; Perese JK; Schuster NM; Oswald JC
    Pain Manag; 2021 Sep; 11(5):437-449. PubMed ID: 33840206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling lasmiditan as a treatment option for migraine.
    Curto M; Cipolla F; Cisale GY; Capi M; Spuntarelli V; Guglielmetti M; Martelletti P; Lionetto L
    Expert Opin Pharmacother; 2020 Feb; 21(2):147-153. PubMed ID: 31766908
    [No Abstract]   [Full Text] [Related]  

  • 9. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
    Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
    J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the 5-HT
    Huang PC; Yang FC; Chang CM; Yang CP
    Prog Brain Res; 2020; 255():99-121. PubMed ID: 33008517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term efficacy and safety of lasmiditan, a novel 5-HT
    Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
    J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is selective 5-HT
    Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lasmiditan: an additional therapeutic option for the acute treatment of migraine.
    Martinelli D; Bitetto V; Tassorelli C
    Expert Rev Neurother; 2021 May; 21(5):491-502. PubMed ID: 33866907
    [No Abstract]   [Full Text] [Related]  

  • 14. Lasmiditan Is a New Option for Acute Migraine Treatment.
    Blakely KK; Stallworth K
    Nurs Womens Health; 2020 Aug; 24(4):294-299. PubMed ID: 32663443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT
    Edvinsson JCA; Maddahi A; Christiansen IM; Reducha PV; Warfvinge K; Sheykhzade M; Edvinsson L; Haanes KA
    J Headache Pain; 2022 Feb; 23(1):26. PubMed ID: 35177004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.
    Lipton RB; Lombard L; Ruff DD; Krege JH; Loo LS; Buchanan A; Melby TE; Buse DC
    J Headache Pain; 2020 Feb; 21(1):20. PubMed ID: 32093628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect and Safety of 5-HT
    Gu P; Chen C; Wu Q; Dong C; Wang T; Wan Q; Dong X
    Biomed Res Int; 2021; 2021():6663591. PubMed ID: 34660796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
    Brandes JL; Klise S; Krege JH; Case M; Khanna R; Vasudeva R; Raskin J; Pearlman EM; Kudrow D
    Cephalalgia; 2019 Oct; 39(11):1343-1357. PubMed ID: 31433669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
    Doty EG; Krege JH; Jin L; Raskin J; Halker Singh RB; Kalidas K
    Cephalalgia; 2019 Oct; 39(12):1569-1576. PubMed ID: 31266353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lasmiditan for the Treatment of Migraines With or Without Aura in Adults.
    Berger AA; Winnick A; Popovsky D; Kaneb A; Berardino K; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2020 Oct; 50(4 Suppl 1):163-188. PubMed ID: 33633424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.